Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged over 18 years at the time of signing the consent form
• People who have been diagnosed with a type of blood cancer called Peripheral T-Cell Lymphoma (PTCL), either newly diagnosed or that has come back or stopped responding to treatment, confirmed by a tissue test
• People with PTCL that has come back or stopped responding to treatment, who have already received at least one previous cancer treatment
• People who are being considered for a stem cell transplant (using their own or a donor's cells) may be able to receive the study drugs as a temporary treatment before the transplant
• People whose disease can be measured or evaluated on scans or tests
• People who are well enough to carry out daily activities, based on a standard medical scoring system (a score of 2 or lower on the ECOG scale)
• People whose liver is working well enough, based on blood test results within accepted ranges (confirm specific values with trial site)
• People whose kidneys are working well enough, based on blood test results within accepted ranges (confirm specific values with trial site)
• People whose blood cell counts are within acceptable levels (confirm specific values with trial site)
• Women who could become pregnant must have a negative pregnancy test before starting, and must agree to use effective contraception during treatment and for at least one month after finishing the study drugs
• Men must agree to use effective contraception during treatment and for at least three months after finishing the study drugs
• People who are willing and able to sign a consent form and understand what the trial involves
• People who are able to attend scheduled visits and follow the trial's requirements

Who may not be able to join:

• People who have previously been treated with drugs that target certain parts of the immune system known as PD-1, PD-L1, or CTLA-4
• People who have previously received too many of the specific drugs being tested in this trial (the exact combination depends on which treatment group is being considered — confirm with trial site)
• People who have received chemotherapy, immunotherapy, biological therapy, radiation, or any experimental cancer treatment within the two weeks before starting the trial, or who still have significant side effects from a previous cancer treatment
• People who have used medications that suppress the immune system within 14 days before the first dose (with some exceptions for low-dose or locally applied steroids — confirm with trial site)
• People who have previously had an allogeneic stem cell transplant (using a donor's cells)
• People with known or suspected allergic reactions to any of the study drugs (durvalumab, pralatrexate, oral 5-azacitidine, or romidepsin) or their ingredients
• People receiving oral 5-azacitidine who have a gut or digestive condition that could prevent the drug from being properly absorbed
• People currently taking certain medications known as CYP3A4 inhibitors (confirm with trial site)
• People with a serious illness that is not currently under control
• People being treated with romidepsin who have certain heart conditions, including but not limited to: a hereditary heart rhythm disorder called long QT syndrome; an abnormal heart rhythm reading on an ECG; a heart attack within the past six months; certain types of heart blockage or very slow heart rate; heart failure; uncontrolled high blood pressure (160/95 or above); a history of serious dangerous heart rhythms; or a heart condition requiring anti-arrhythmia medication (excluding stable beta-blockers) — confirm full list with trial site
• People who are pregnant or breastfeeding
• People who have another active cancer (exceptions may apply for certain minor skin cancers, early prostate changes, or early cervical cell changes — confirm with trial site)
• People who have received a solid organ transplant (such as a kidney or liver transplant)
• People who have had an active autoimmune or inflammatory condition (such as lupus, Crohn's disease, rheumatoid arthritis, or similar conditions) within the past three years before starting treatment — some exceptions may apply (confirm with trial site)
• People with lymphoma that has spread to the brain or spinal fluid
• People with a currently active hepatitis A, B, or C infection
• People with a known HIV infection
• People with a history of a primary immune deficiency condition
• People who have received a live vaccine within 30 days before joining the trial, or who would need one during the trial or within 30 days after the last dose of durvalumab

Important: Always verify eligibility with the trial site directly before applying.